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Edited by Frances ShannonAbstract Nuclear factor kappa B (NF-jB) plays a wide variety
of pathophysiological roles and modulation of its pathway can be
a good novel drug target. Here, we found that our recently
synthesized NF-jB inhibitor attenuated an ovalbumin-speciﬁc
delayed-type hypersensitivity response in vivo and suppressed
production of IL-12 by dendritic cells and TH1 cytokines by T
cells in vitro. These ﬁndings suggest that the activation of NF-jB
mounts TH1 type immune responses, and that this new NF-jB
inhibitor has a therapeutic potential in this context.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Nuclear factor kappa B (NF-jB) family of transcription
factors exist as homodimers or heterodimers of ﬁve distinct
proteins (p50, p52, p65, RelB, and cRel) [1]. NF-jB proteins
are present in the latent cytoplasm bound to inhibitors of NF-
jB (IjBs). After activation by inducers, IjB proteins are
phosphorylated, ubiquitylated, and degraded by the protea-
some. The degradation of IjB allows NF-jB proteins to
translocate to the nucleus and to bind their cognate DNA
binding sites, which regulates the transcription of a large
number of genes, including antimicrobial peptides, cytokines,
chemokines, and stress-responses proteins [2]. Several studies
have shown that the activation of NF-jB plays roles in a
number of inﬂammatory conditions such as asthma, rheuma-
toid arthritis, heart disease, and dermatitis [3,4]. Based on
these ﬁndings, inhibition of NF-jB transcriptional activation
may represent an attractive target in the development of novel
anti-inﬂammatory drugs. Many pharmaceutical companies
have tried to develop selective inhibitors of NF-jB, including* Corresponding author. Fax: +81-75-761-3002.
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doi:10.1016/j.febslet.2004.10.065targeting the DNA-binding activity of individual NF-jB pro-
teins using decoy oligonucleotides [4–6]. Recently, synthetic
decoy oligonucleotides containing the NF-jB cis element have
prevented a certain number of diseases as myocardial infarc-
tion and rheumatoid arthritis [5,7,8]. However, there has been
no satisfactory NF-jB inhibitory compound for in vivo use at
present.
Antigen-speciﬁc immune responses are involved in the
pathogenesis of a variety of diseases. To establish this re-
sponse, the interaction between T cells and antigen presenting
cells, as dendritic cells, is essential for clonal stimulation and
diﬀerentiation from na€ıve CD4þ cells into helper T cells. There
are two diﬀerent fates of helper T cells, TH1 cells expressing IL-
2 and IFN-j involved in cellular immunity, and Th2 cells re-
leasing IL-4, IL-5, IL-6, IL-10 and IL-13, mediating humoral
immunity [9]. In this step, IL-12 produced by dendritic cells is
dominant in directing the development of TH1 cells [10], and it
is reported that NF-jB functions in T cell activation, TH1
diﬀerentiation, and dendritic cell maturation [3,4,11–14]. These
in vitro studies suggest that NF-jB plays an important role in
antigen-speciﬁc TH1 type immune responses in vivo.
Here, we report that a newly synthesized NF-jB inhibitor
functions speciﬁcally to NF-jB activity in vitro and suppressed
antigen-speciﬁc delayed-type hypersensitivity (DTH) response
as a TH1 type immune response model.2. Materials and methods
2.1. Materials
C57BL/6 female mice were used as mentioned otherwise and all
animal experiments were approved by the Committee on Animal Re-
search of Kyoto University. DSKB-2, a new NF-jB inhibitor, was
synthesized in our laboratory [19]. For in vivo experiments, this
compound was applied intraperitoneally (1 mg/kg) to mice twice a day
until the end of experiments, or topically on the ear skin at a dose of 20
ll of 0.1 mg/ml acetone solution. DSKB-2 was applied to mice 5 min
after ultraviolet (UV) irradiation or 1 h before ovalbumin (OVA)
sensitization.
2.2. Cell preparation, culture, and luciferase assay
Cells were prepared from the spleen essentially as previously de-
scribed [15]. Splenic CD11cþdendritic cells and CD4þ T cells were
puriﬁed with beads-conjugated antibodies to CD11c and CD4 using an
Auto MACS (Miltenyi Biotec, Gladbach, Germany). The puriﬁed cells
were shown to be more than 80% positive for CD11cþand 95% positive
for CD4þ cells conﬁrmed by ﬂow cytometry EPICS XL instrument
(Beckman Coulter, Fullerton, CA). The cells were cultured in ﬂat-
bottomed 96-well plates at 37 C as described [16]. For T cell prolif-
eration, CD4þ cells (2 105/well) were activated in plates precoatedation of European Biochemical Societies.
Fig. 1. Eﬀect of DSKB2 on SV-40, CRE, and NF-jB. A549 cells
transfected with constitutive SV40 driven luciferase gene exhibited the
luciferase activity. And A549 cells transfected with CRE driven lucif-
erase gene exhibited the luciferase activity in the presence of cAMP.
Both of these activities were not aﬀected by the exposure of DSKB2 at
indicated doses. On the other hand, when A549 cells with NF-jB
driven luciferase gene were stimulated with IL-1 for 4 h, DSKB2
inhibited the luciferase activity in a dose dependent manner. Data
shown are representatives of three independent experiments, showing
meansS.E.M. in triplicated wells.
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licate. For mixed lymphocyte reaction, dendritic cells (6 104/well)
isolated from the spleen of BALB/c mice were irradiated and cultured
for 72 h in triplicate with allogeneic CD4þ cells (2 105/well) from the
spleen of C57BL/6 mice. The proliferation of CD4þ cells was deter-
mined as incorporation of [3H]thymidine for the last 16 h as described
[16]. The amounts of IL-2, IFN-j and IL-12 at 72 h of culture were
measured by EIA kits (Biotrak) as per the manufacturer’s protocols.
For luciferase assay, luciferase plasmid containing the NF-jB,
constitutively active SV40, or cyclic AMP responsive element (CRE)
consensus sequence was co-transfected with pSV2neo (Clontech, USA)
into A549 cells using lipofectamine (Lifetech Oriental K.K., Tokyo),
and selected by adding G418 sulfate (1 mg/ml, Lifetech Oriental K.K.).
2.3. Preparation of nuclear extracts and electrophoretic mobility shift
assays (EMSA)
The nuclear extracts from the spleens of OVA-sensitized mice were
isolated according to the method of Schreiber et al. [17] with a slight
modiﬁcation. Brieﬂy, the spleens from four mice that received vehicle
or NF-jB inhibitor for indicated period were minced and homogenized
in cold buﬀer I (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA,
0.1 mM EGTA, 1 mM DTT, and 1 mM phenylmethylsulfonyl ﬂuo-
ride) with a tissue homogenizer. The homogenates were allowed to
swell on ice for 10 min, mixed with 10% NP-40, and vortexed for 10 s.
The homogenates were centrifuged for 10 min. After removal of the
supernatant, the nuclear pellets were resuspended in buﬀer II (20 mM
HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM
DTT, and 1 mM PMSF). The nuclear extracts were centrifuged and
the supernatants were used. The DNA probe consisted of the NF-jB
consensus sequence (50-AGTTGAGGGGACTTTCCCAGGC-30) or
AP-1 consensus sequence (50-CGCTTGATGACTCAGCCGGAA-30).
The oligonucleotide 50-labeled with rhodamine and unlabeled oligo-
nucleotides were purchased from Amersham Pharmacia Biotech (To-
kyo, Japan). The nuclear extracts (5 lg/ml) were incubated with
rhodamine-labeled NF-jB probe in the binding buﬀer (20 mM HE-
PES, pH 7.6, 1 mM EDTA, 10 mM (NH4)2SO4, 1 mM DTT, 30 mM
KCl, and 0.2% (w/v) Tween 20) at room temperature for 15 min. The
nuclear protein and oligonucleotides complexes were separated from
free probes on native 5% polyacrylamide gel (BioRad, Richmond, CA)
in 0.25 TBE (Tris–borate–EDTA) buﬀer. The gel was scanned using
a ﬂuorescent image analyzer (FMBIO II; Hitachi, Yokohama, Japan).
2.4. UV radiation
Mice were anesthetized and the dorsal ears of mice were exposed to a
bank of ﬂuorescent sunlamps (FL.20SE.30; Toshiba Medical Supply,
Tokyo, Japan) with an emission spectrum from 270 to 375 nm, peaking
at 305 nm from above at a dose of 3 kJ/m2 [18]. The irradiance of UVB
was measured by a radiometer (UVR-305/365D (ll); Toshiba Medical
Supply).2.5. DTH response
For an OVA-induced DTH, mice were sensitized by intraperitoneal
injection of 100 lg of OVA (Sigma) in complete Freund’s adjuvant.
Seven days later, mice were injected subcutaneously with 30 lg of OVA
in incomplete Freund’s adjuvant into a hind footpad. The change in
footpad thickness was measured 48 h after the challenge by subtracting
the thickness of the contralateral footpad injected with incomplete
Freund’s adjuvant alone from that of the footpad injected with both
OVA and adjuvant.
2.6. Statistics
Data are presented as meansS.E.M. and were analyzed by Stu-
dent’s unpaired two-tailed t test. A P value of <0.05 was considered
statistically signiﬁcant.3. Results
3.1. Speciﬁcity of a new NF-jB inhibitor, DSKB-2, in vitro
DSKB-2, a new NF-jB inhibitor, is an indan derivative with
inhibition of NF-jB transcriptional activation in A549 cells
stimulated with TNF-a or IL-1b (TNF-b: IC50¼ 89 nM; IL-
1b; IC50¼ 51 nM) and in Jurkat cells (IC50¼ 38 nM,
TC50¼>10 000 nM) [19,20]. Initially, we assessed this com-
pound’s speciﬁcity to NF-jB in vitro. When A549 cells
transfected with NF-jB driven luciferase gene were stimulated
with IL-1 (1 ng/ml) for 4 h, DSKB-2 inhibited the luciferase
activity in a dose dependent manner. On the other hand, when
A549 cells transfected with constitutively active SV40 or CRE
driven luciferase genes, which was independent of the activa-
tion of NF-jB, were stimulated with or without cAMP (1
mM), the luciferase activities were not aﬀected by the exposure
of DSKB-2 (Fig. 1). These data suggested that DSKB-2 in-
hibited the activation of NF-jB speciﬁcally in vitro.3.2. In vivo impact of a new NF-jB inhibitor on UV-induced
skin inﬂammation
Since the in vitro eﬀect of NF-jB has been evaluated as
above, we then evaluated the in vivo eﬀect of this compound. It
is known that a single dorsal exposure of mouse skin to UV
radiation causes marked cutaneous inﬂammation and that the
extent of inﬂammation can be examined by measuring the ear
swelling responses. It was previously reported that ear swelling
became detectable within 24 h after irradiation and progressed
over the next several days, and this ear swelling was signiﬁ-
cantly reduced by blocking NF-jB gene transactivation with
NF-jB decoy oligonucleotides [18]. Therefore, using UV-
induced skin inﬂammation assay, we initially conﬁrmed an in
vivo eﬀect of DSKB-2. Mice treated with intraperitoneal in-
jections or skin painting of DSKB-2 showed signiﬁcantly re-
duced ear swelling responses to UV irradiation at a dose of 3
kJ/m2 at each time point tested after 72 h compared with
control mice with PBS treatment (Fig. 2). These present results
suggest that the DSKB-2 functions eﬃciently in vivo.
3.3. Impaired DTH response by the new NF-jB inhibitor
Using DTH as a TH1 immune response model, we investi-
gated the eﬀect of NF-jB in an acquired immune response to
an exogenous antigen. We sensitized mice with an intraperi-
toneal injection of OVA mixed with complete Freund’s adju-
vant. Seven days later, we challenged the mice with a
subcutaneous injection of OVA mixed with incomplete Fre-
und’s adjuvant into a hind footpad. The extent of footpad
swelling was signiﬁcantly reduced by intraperitoneal injection
Fig. 4. Eﬀect of a new NF-jB inhibitor on NF-jB activity in the spleen
from OVA-sensitized mice. Mice were treated with or without DSKB-2
and immunized with OVA. Nuclear proteins were extracted from the
spleens on day 0, 1, and 5 after immunization. The nuclear extracts
were incubated with rhodamine-labeled NF-jB probe and its activity
of each sample was analyzed by EMSA as indicated (A). Using the
nuclear extracts from the spleen of mice 5 days after OVA immuni-
zation, the speciﬁcity of NF-jB/DNA binding reaction was examined
in the presence or absence of a 100-fold molar excess of unlabeled
oligonucleotide containing AP-1 and NF-jB (B, left panel) or anti-
bodies to p50 and p65 (B, right panel). Arrowheads indicate the NF-
jB band.
Fig. 2. Inhibition of UV-induced ear skin swelling by application of
NF-jB inhibitor. C57BL/6 mice treated with an intraperitoneal injec-
tion of NF-jB inhibitor DSKB-2 (closed circles), PBS alone (closed
triangles), or topical application of DSKB-2 (closed square). These
mice were exposed to UV radiation at a dose of 3 kJ/m2 and examined
for ear swelling responses at the indicated time points. Data shown are
representative of three independent experiments, showing means
S.E.M. (n¼ 4) of ear thickness change compared before irradiation.
Statistically signiﬁcant diﬀerences (P<0.05) compared with the
UV plus PBS group (# vs. intraperitoneal injection, and *vs. topical
application group).
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from the spleen at each indicated time after OVA sensitization
and examined NF-jB activity using EMSA. This experiment
showed that NF-jB activity is induced both one and ﬁve days
after OVA sensitization and this induction is attenuated by the
DSKB-2 (Fig. 4A). Since dendritic cell maturation occurs 1
day after sensitization, and T cells proliferate and diﬀerentiate
3–6 days after sensitization, the above data suggest that NF-
jB activity is induced at two diﬀerent phases, early phase (day
1) during dendritic cell maturation, and later phase (day 5)
during T cell activation and diﬀerentiation into TH1. More-
over, we conﬁrmed the speciﬁcity of NF-jB/DNA binding
reaction using the nuclear extracts from the spleen of mice 5
days after OVA. The nuclear extracts were incubated with
rhodamine labeled oligonucleotide containing a consensus NF-
jB binding site in the presence or absence of a 100-fold molar
excess of unlabeled oligonucleotide containing AP-1 and NF-Fig. 3. Impaired OVA-speciﬁc DTH response by NF-jB inhibitor.
Mice were sensitized by intraperitoneal injection of OVA and complete
Freund’s adjuvant. Footpad swelling induced by OVA challenge in
sensitized mice (n¼ 6 per group) was measured. Footpad swelling
treated with DSKB-2 is signiﬁcantly impaired compared to vehicle
treated mice (*P<0.05).jB (Fig. 4B, left panel), where the NF-jB band is disappeared
by unlabeled oligonucleotide containing NF-jB, but not by
unlabeled oligonucleotide containing AP-1. Moreover, the
NF-jB band is supershifted by the presence of antibodies to
p50 and p65 which constitute NF-jB (Fig. 4B, right panel).
These results clariﬁed that the band observed does indeed
represent binding of NF-jB.
3.4. NF-jB inhibitor attenuates dendritic cell activation and T
cell proliferation in vitro
The above results suggested that NF-jB regulated dendritic
cell and/or T cell function. To examine this issue, we ﬁrst ex-
amined the eﬀect of DSKB-2 in dendritic cell-independent T
cell proliferation stimulated by anti-CD3 antibody and found
that DSKB-2 attenuated T cell proliferation in a dose depen-
dent manner (Fig. 5A). Consistently, DSKB-2 inhibited the
production of TH1 cytokines, IL-2 and IFN-c (Fig. 5B and C).
On the other hand, DSKB-2 did not suppress the TH2 cyto-
kine, IL-4, production in this assay (data not shown). Since the
above T cell proliferation assay is independent of dendritic cell
function, we then performed a mixed lymphocyte reaction
assay where splenic C57BL/6 CD4þ T cells were stimulated by
irradiated allogeneic splenic BALB/c dendritic cells. This
dendritic cell dependent CD4þ T cell proliferation was signif-
icantly attenuated by DSKB-2 in a dose dependent manner
(Fig. 6A). Moreover, the NF-jB inhibitor suppressed both the
production of TH1 cytokine (IL-2 and IFN-c) by TH1 cells,
and the production of IL-12, which is dominant in directing
the development of TH1 cells and is produced by dendritic cells
(Fig. 6B–D). Therefore, these above results suggest that NF-
jB drives TH1 type immune responses by acting not only on
dendritic cells but also on T cells.
Fig. 5. Eﬀect of NF-jB inhibitor on dendritic cell-independent T cell proliferation and cytokine production stimulated with anti-CD3 antibody. (A–
C) CD4þ cells puriﬁed from the spleen of C57BL/6 mice were stimulated by stabilized anti-CD3 antibody in the absence (0 nM) or presence of the
NF-jB inhibitor (DSKB-2) for 72 h in triplicates. T cells without anti-CD3 stimulation are indicated as aCD3()). The doses of DSKB-2 are as shown
on the graph. T cell proliferation (A), the production of IL-2 (B), and IFN-c (C) were determined. *P <0.05 vs. vehicle treated (0 nM) group.
Representative data from more than three independent experiments are shown.
Fig. 6. Eﬀect of NF-jB inhibitor on T cell proliferation and cytokine production stimulated with allogeneic dendritic cells. CD4þ cells from the
spleen of C57BL/6 mice were stimulated with or without (DC())) irradiated dendritic cells from the spleen of BALB/c mice in the presence or absence
of the DSKB-2. T cell proliferation (A), production of IL-2 (B), IFN-c (C), and IL-12 (D) were determined. *P<0.05 vs. vehicle (0 nM) treated
group. Representative data from more than three independent experiments are shown.
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In the present study, we showed that a newly synthesized
NF-jB inhibitor speciﬁcally acted on NF-jB activity in vitro
and attenuated antigen-speciﬁc TH1 type DTH response in
vivo. Consistently, this compound suppressed not only T cell
proliferation and TH1diﬀerentiation, but also dendritic cell
function in vitro.
There are a number of in vitro studies about the role of NF-
jB on dendritic cells and T cells. It has recently been reported
that NF-jB blocked dendritic cells with adenovirus transfer-
ring IjBa and impaired the allogeneic immune reaction, which
suggested that the antigen presentation by dendritic cells in
vivo is NF-jB dependent [21]. However, the precise roles of
NF-jB on antigen-speciﬁc acquired immune response in vivo
have still not been well investigated. In our study, we ﬁrst
demonstrated that our new NF-jB inhibitor attenuated an
antigen-speciﬁc acquired DTH response, and that NF-jB ac-
tivity is induced not only during dendritic cells maturation
phase, but also during T cells proliferation and diﬀerentiation
phase, both of which were suppressed by the NF-jB inhibitor.
Interestingly, this inhibitor attenuated both dendritic cell-in-
dependent and dependent T cell proliferation, but the extent of
suppression by this compound is much more dramatic in a
dendritic-dependent T cell proliferation assay. Moreover, we
found that this compound suppressed both the production of
TH1 cytokines by TH1 cells and the production of IL-12 pro-
duced by dendritic cells in vitro. These above results suggest
that NF-jB pathway is essential to establish an antigen-spe-
ciﬁc acquired DTH response, by functioning both during
dendritic cells maturation and T cell proliferation and diﬀer-
entiation phase.
Every eﬀort has been made to develop selective inhibitors of
NF-jB in vivo, however, no satisfactory NF-jB inhibitory
compound for in vivo use has been developed yet. We dem-
onstrated that our new NF-jB inhibitor is speciﬁc to NF-jB
activity in vitro and suppressed DTH response in vivo in ac-
cordance with the local inhibition of NF-jB activity. Inﬂam-
matory response activates multiple transcription factors,
including NF-jB, AP-1, and AP-2 [22,23]. They are by no
means mutually exclusive; rather, they operate in an interde-
pendent manner. Therefore, although we could show the
compound speciﬁcity to NF-jB activity in vitro, it is diﬃcult
to show the in vivo speciﬁcity of this compound. However, the
ear-swelling response induced by skin irritant chemical paint-
ing with phorbol myristate acetate or dinitroﬂuorobenzene was
not aﬀected by the compound (data not shown), which ex-
cluded the possibility that this compound had acted simply as
a non-speciﬁc anti-inﬂammatory agent.
Since antigen-speciﬁc acquired immune responses are in-
volved in a lot of clinical settings, this compound has potentialimplications for a wide variety of therapeutic uses, including
allergy, autoimmunity, and transplantation. We showed that
the new NF-jB inhibitor does not aﬀect the TH2 cytokine
production in vitro, but it would be interesting to further ex-
amine the eﬀect of this compound on TH2 immune response in
vivo. On the other hand, NF-jB is also involved in normal
cellular physiology. The global inhibition of NF-jB could re-
sult in serious side eﬀects as hepatotoxicity during embryonic
development. In this respect, this new NF-jB inhibitor is ef-
ﬁcient even by topical use in UV-induced skin inﬂammation.
Therefore, this compound would be a good candidate for the
control of local inﬂammation as contact hypersensitivity,
psoriasis, and atopic dermatitis without serious systemic side
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